None
Quote | Armata Pharmaceuticals Inc. (NYSE:ARMP)
Last: | $3.30 |
---|---|
Change Percent: | -1.01% |
Open: | $3.01 |
Close: | $3.30 |
High: | $3.4154 |
Low: | $3 |
Volume: | 15,957 |
Last Trade Date Time: | 07/17/2024 03:00:00 am |
News | Armata Pharmaceuticals Inc. (NYSE:ARMP)
Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection PR Newswire Tail wind is evaluating inhaled AP-PA02 in non-cystic fib...
Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024 PR Newswire LOS ANGELES , July 10, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the...
Message Board Posts | Armata Pharmaceuticals Inc. (NYSE:ARMP)
Subject | By | Source | When |
---|---|---|---|
Interesting article. | gumshoe22 | investorshub | 07/08/2022 4:18:38 PM |
Here's an interesting article on how a bacteriophage | lesgetrich | investorshub | 01/15/2022 4:20:37 PM |
ARMATA MORE GOOD NEWS FDA Clearance | gator16 | investorshub | 11/18/2021 2:28:35 PM |
There was a PR last Friday... | lesgetrich | investorshub | 11/03/2021 3:50:03 PM |
Do I detect a pulse? | gumshoe22 | investorshub | 11/03/2021 3:31:52 PM |
News, Short Squeeze, Breakout and More Instantly...
Armata Pharmaceuticals Inc. Company Name:
ARMP Stock Symbol:
NYSE Market:
Armata Pharmaceuticals Inc. Website:
Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection PR Newswire Tail wind is evaluating inhaled AP-PA02 in non-cystic fib...
Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024 PR Newswire LOS ANGELES , July 10, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the...